title: Erythrocyte vitamins B1, B2 and B6 and erythropoietin.
abstract: The influence of recombinant human erythropoietin (r-HuEPO) on erythrocyte vitamins B1, B2 and B6 was investigated in regular dialysis treatment (RDT) patients during a long-term 9-month study. Twenty-six RDT patients were divided into two groups. Group A was without r-HuEPO treatment while group B was treated by subcutaneous injection of r-HuEPO. The total maintenance weekly dose of r-HuEPO was 50-100 U/kg. Group A of patients was supplemented with oral pyridoxine 5 mg/day during the period of 9 months; group B was supplemented with oral pyridoxine 5 mg/day for the first 6 months and with 20 mg/day during the following 3 months. At the end of the study, significant increase in erythrocyte vitamin B2 and significant decrease in erythrocyte vitamin B6 were found. Supplementation with 20 mg/day of pyridoxine led to a significant increase in vitamin B6 and at the end of the 9 months, the values of vitamin B6 were within the normal range. These results provide indirect evidence that erythrocyte vitamin B6 is consumed by the hemoglobin synthesis during r-HuEPO treatment in RDT patients.
authors.affiliation: Fourth Medical Clinic, University Hospital of Louis Pasteur, Kosice, Slovak Republic.
authors.forename: M
authors.initials: M
authors.lastname: Mydlik
authors.forename: K
authors.initials: K
authors.lastname: Derzsiová
mesh_terms: D000740:Anemia / Q000188:drug therapy / Q000209:etiology; D004912:Erythrocytes / Q000378:metabolism*; D004921:Erythropoietin / Q000627:therapeutic use*; D006801:Humans; D007676:Kidney Failure, Chronic / Q000150:complications / Q000628:therapy; D011736:Pyridoxine / Q000097:blood* / Q000627:therapeutic use; D011994:Recombinant Proteins / Q000627:therapeutic use*; D006435:Renal Dialysis; D012256:Riboflavin / Q000097:blood*; D013831:Thiamine / Q000097:blood*; D013997:Time Factors
chemical_list: D011994:Recombinant Proteins; D004921:Erythropoietin; D011736:Pyridoxine; D012256:Riboflavin; D013831:Thiamine